As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study We divided the borrowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results